| | Outliers were defined as subjects with a standing systolic blood pressure of < 85 mmHg or a decrease from baseline in standing systolic blood pressure of > 30 mmHg at one or more timepoints. The mean profiles of the change from baseline in standing systolic blood pressure in subjects treated with doxazosin in combination with 25 mg FILDENA or matching placebo are shown in Figure 2. For the 17 subjects who received FILDENA 25 mg and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95 I) in systolic blood pressure were as follows:
In the first study, a single oral dose of FILDENA 100 mg or matching placebo was administered in a 2-period crossover design to 4 generally healthy males with benign prostatic hyperplasia (BPH). Figure 1: Mean Change from Baseline in Sitting Systolic Blood Pressure, Healthy Volunteers. The decrease in sitting blood pressure was most notable approximately 1-2 hours after dosing, and was not different than placebo at 8 hours.
The erectile response, as assessed by RigiScan®, generally increased with increasing Filagra dose and plasma concentration. Effects of FILDENA on Erectile Response. Filagra at recommended doses has no effect in the absence of sexual stimulation.
When sexual stimulation causes local release of NO, inhibition of PDE5 by Filagra causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. FILDENA is contraindicated in patients with a known hypersensitivity to Filagra, as contained in FILDENA and REVATIO, or any component of the tablet. Consistent with its known effects on the nitric oxide/cGMP pathway see CLINICAL PHARMACOLOGY , FILDENA was shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated.
There was no impairment of fertility in rats given Filagra up to 60 mg/kg/day for 36 days to females and 102 days to males, a dose producing an AUC value of more than 25 times the human male AUC. Physicians should advise patients to stop use of all PDE5 inhibitors, including FILDENA, and seek medical attention in the event of a sudden loss of vision in one or both eyes. To decrease the chance of adverse reactions in patients taking ritonavir, a decrease in Filagra dosage is recommended see DOSAGE AND ADMINISTRATION , DRUG INTERACTIONS , and CLINICAL PHARMACOLOGY.
Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure when taking a PDE5 inhibitor. Physicians should advise patients to stop taking PDE5 inhibitors, including FILDENA, and seek prompt medical attention in the event of sudden decrease or loss of hearing.
https://www.bumc.bu.edu/busm-pm/academics/resources/glossary/
https://www.forhims.com/blog/the-most-common-erectile-dysfunction-treatments
https://fildenas.net/
https://www.ecpi.edu/college-of-health-science
https://digitalcommons.pepperdine.edu/cgi/viewcontent.cgi?referer=https://www.google.com/&httpsredir=1&article=1570&context=naalj
| | | |
|